|
[18F]F-AraG Clinical Trials
1 actively recruiting trial across 1 location
No change since May 2026
Also known as: VisAcT
Pipeline
Phase 2: 1
Top Sponsors
- CellSight Technologies, Inc.1
Indications
- Advanced Non-Small Cell Lung Cancer1
- Lung Cancer1
- Cancer1
Iowa City, Iowa1 trial
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
University of Iowa Hospitals and Clinics
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.